CD5L: Scavenger Receptor Cysteine-Rich Protein and Immune Regulator
Comprehensive genomic, transcriptomic, and proteomic analysis of CD5L (CD5 Molecule Like) – a secreted glycoprotein involved in apoptosis, lipid metabolism, and inflammatory disease.
Gene Information Card
| Symbol | CD5L |
|---|---|
| Full Name | CD5 Molecule Like |
| Gene Type | Protein coding |
| Chromosomal Location | 1q21.3 |
| NCBI Gene ID | 922 ncbi.nlm.nih.gov/gene/922 |
| Ensembl ID | ENSG00000173762 |
| UniProt ID | O43866 |
| OMIM ID | 602249 |
| HGNC ID | 1690 |
| Aliases | AIM, SP-alpha, CT-2, API6, PRO2290 |
Description
CD5L (CD5 Molecule Like) encodes a secreted glycoprotein belonging to the scavenger receptor cysteine-rich (SRCR) superfamily. The protein is primarily produced by macrophages and acts as an apoptosis inhibitor, regulating lipid metabolism, inflammation, and immune responses. It is also known as AIM (apoptosis inhibitor of macrophages) or SP-alpha.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Atherosclerosis | CD5L promotes macrophage survival and lipid accumulation, contributing to plaque formation. | PMID: 29127259 |
| Non-alcoholic fatty liver disease (NAFLD) | CD5L modulates hepatic lipid metabolism and inflammation. | PMID: 31570887 |
| Rheumatoid arthritis | CD5L is elevated in synovial fluid and may regulate inflammatory cytokine production. | PMID: 24608435 |
| Colorectal cancer | CD5L expression is associated with tumor progression and immune evasion. | PMID: 31073040 |
| Sepsis | CD5L levels correlate with severity and outcome in septic patients. | PMID: 28289147 |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Liver | 12.5 | Medium |
| Spleen | 8.2 | Medium |
| Lung | 6.1 | Low |
| Adipose tissue | 4.8 | Low |
| Small intestine | 3.9 | Low |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| THP-1 (macrophage) | 15.3 | Differentiated with PMA |
| HepG2 | 10.1 | Hepatocellular carcinoma |
| A549 | 2.4 | Lung adenocarcinoma |
| MCF7 | 1.2 | Breast cancer |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.374C>T (p.Thr125Met) | Missense | 0.0002 (gnomAD) | Unknown functional effect |
| c.538G>A (p.Gly180Ser) | Missense | 0.0001 (gnomAD) | Unknown functional effect |
| c.784C>T (p.Arg262Trp) | Missense | 0.0003 (gnomAD) | Unknown functional effect |
Mutation functional classification
Loss of Function (LOF)
No confirmed loss-of-function mutations reported in CD5L.
Gain of Function (GOF)
No confirmed gain-of-function mutations reported in CD5L.
Dominant Negative (DN)
No confirmed dominant-negative mutations reported in CD5L.
View complete mutation data：
Gene Ontology (GO)
Pathways
• Phagosome (KEGG: hsa04145)
• Lysosome (KEGG: hsa04142)
• Scavenger receptor activity (Reactome: R-HSA-3000480)
Protein Summary
CD5L is a 347-amino-acid secreted glycoprotein (UniProt O43866) containing three scavenger receptor cysteine-rich (SRCR) domains. It is synthesized as a preproprotein and cleaved to yield the mature form. CD5L binds to various ligands including oxidized LDL, bacteria, and apoptotic cells, modulating macrophage survival, lipid uptake, and inflammation. The protein is heavily glycosylated and forms homomultimers.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| CD5L Knockout HEK293 Cell Line | EDJ-KQ4216 | Human | 922 | Details Get a Quote |
| CD5L Knockout HeLa Cell Line | EDJ-KQ52817 | Human | 922 | Details Get a Quote |
| CD5L Knockout A-549 Cell Line | EDJ-KQ61288 | Human | 922 | Details Get a Quote |
| CD5L Knockout HCT 116 Cell Line | EDJ-KQ69783 | Human | 922 | Details Get a Quote |
Displaying Records 1 To 4 Of 4 Records
